NeOnc Adds Strategy Executive Nasim Shomali to Board Amid Clinical Milestones
Event summary
- Nasim Shomali joined NeOnc’s Board of Directors on July 1, 2026.
- Shomali brings over a decade of experience in strategy and finance, most recently as a Strategy Executive at Accenture.
- NeOnc is advancing NEO100™ and NEO212™ through Phase II clinical trials under FDA Fast-Track designation.
The big picture
NeOnc’s appointment of Nasim Shomali reflects a strategic move to strengthen governance as it navigates critical clinical and regulatory milestones. Her expertise in both finance and biomedical engineering aligns with NeOnc’s focus on overcoming the blood-brain barrier, a persistent challenge in CNS cancer treatment. The addition comes at a pivotal time for the company as it seeks to expand its development efforts internationally.
What we're watching
- Clinical Execution
- How NeOnc’s Phase II trials for NEO100 and NEO212 will progress under Shomali’s strategic oversight.
- Capital Allocation
- Whether Shomali’s disciplined approach to capital allocation will influence NeOnc’s international expansion plans.
- Regulatory Milestones
- The pace at which NeOnc can secure additional regulatory approvals for its CNS cancer therapies.